stockrow
Friday 6 November 2026
Export NVCR’s income statement to Excel — free account
NovoCure Limited
NVCR Healthcare Medical Devices
NovoCure Limited’s revenue for fiscal 2025 (year ended December 2025) was $655.4 million, up 8.28% from fiscal 2024.
- Revenue
- +15.7%
- EPS
- +72.9%
- Free cash flow
- +5.54%
- Total debt
- +0.87%
Quarter to September 2026, against a year earlier
13.26
0.29
−2.14%
Follow NVCR
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | 3 | 3 | 4 |
+8 more TTM periods Free account |
| (35.18%) | (43.22%) | (49.96%) | (38.89%) | ||
| (11.12%) | (14.56%) | (16.99%) | (13.32%) | ||
ROIC |
(106.10%) | (115.56%) | (92.52%) | (123.24%) | |
Return on Tangible Assets |
(24.16%) | (28.58%) | (33.69%) | (26.04%) | |
Average Days of Receivables |
80.17 | 76.12 | 79.24 | 82.49 | |
Free Cash Flow per Share |
(0.21) | (0.22) | (0.42) | (0.68) | |
Free Cash Flow |
(24.61) | (25.43) | (48.07) | (75.68) | |
Capital Expenditures |
(23.88) | (22.62) | (21.19) | (26.65) | |
| Other line items | |||||
Cash ROIC |
(2.41%) | (2.58%) | (4.77%) | (7.62%) | |
Accounts Receivable Turnover |
5.11 | 5.09 | 5.09 | 5.09 | |
Accounts Payable Turnover |
1.26 | 1.42 | 1.50 | 1.47 | |
Inventory Turnover |
4.18 | 4.05 | 4.03 | 4.38 | |
Average Days of Payables |
319.46 | 285.86 | 277.62 | 267.35 | |
Days of Inventory on Hand |
88.90 | 92.33 | 94.82 | 89.92 | |
Tax Rate |
(0.07) | (0.03) | (0.01) | 0.00 | |
Research and Development Expense of Revenue |
31.54% | 32.14% | 33.97% | 34.26% | |
Selling, General and Administrative Expense of Revenue |
62.65% | 66.07% | 68.41% | 63.74% | |
Share Based Compensation of Revenue |
16.17% | 18.47% | 20.51% | 16.00% | |
Interest Coverage |
(20.76) | 90.29 | 22.52 | 8.76 | |
Operating CF/Net income |
0.01 | 0.02 | 0.16 | 0.36 | |
Depreciation/Fixed assets |
0.05 | 0.01 | (0.04) | (0.09) | |
Capex/Depreciation |
(4.34) | (23.71) | 5.61 | 3.09 | |
Revenue per Share |
6.21 | 6.03 | 5.91 | 5.88 | |
Operating CF per Share |
(0.01) | (0.02) | (0.24) | (0.44) | |
Capex per Share |
(0.20) | (0.19) | (0.19) | (0.24) | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.04 |
Columns are period end dates · fundamentals updated 2 Nov 2026